Mucoadhesive chitosan microspheres of carvedilol for nasal administration

The aim of the present study was to develop and characterize chitosan mucoadhesive microspheres of carvedilol (CRV) for nasal delivery to improve bioavailability for treatment of hypertension and angina pectoris. The microspheres were prepared by emulsification-cross-linking method and evaluated for size, shape, entrapment efficiency (EE), in vitro mucoadhesion, in vitro drug release, differential scanning calorimetry (DSC) and X-ray diffraction (XRD). The mucoadhesive properties were also evaluated by Freundlich and Langmuir adsorption isotherms. In vivo tests were carried out in rabbits. The microspheres were spherical with size of 20–50 µm, which is favorable for intranasal absorption. The EE was observed from 42% to 68% while percentage mucoadhesion was from 74% to 88%. A strong interaction between mucin and chitosan microspheres was detected explaining adsorption with electrostatic interaction. The microspheres released around 75% of drug in 8 h. DSC and XRD studies revealed that CRV was molecularly dispersed. The absorption rate was rapid and the absolute bioavailability was high, 72.29%. The gamma scintigraphy indicated that the microspheres cleared slowly from the nasal cavity. It was concluded that chitosan microspheres could be used to deliver CRV following nasal administration for improving the bioavailability.

[1]  P. Giunchedi,et al.  Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  P. Paronen,et al.  Double-labelling technique in the evaluation of nasal mucoadhesion of disodium cromoglycate microspheres , 1991 .

[3]  E. Denkbaş,et al.  5-fluorouracil loaded chitosan microspheres for chemoembolization. , 1999, Journal of microencapsulation.

[4]  Nicholas A. Peppas,et al.  A simple equation for description of solute release II. Fickian and anomalous release from swellable devices , 1987 .

[5]  L. Illum.  Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Dahl,et al.  Anatomy, physiology and function of the nasal cavities in health and disease. , 1998, Advanced drug delivery reviews.

[7]  Hans Bisgaard,et al.  Bioadhesive microspheres as a potential nasal drug delivery system , 1987 .

[8]  P. Giunchedi,et al.  Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in‐vitro/ex‐vivo studies , 2005, The Journal of pharmacy and pharmacology.

[9]  K. Sawant,et al.  Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery , 2009, Journal of microencapsulation.

[10]  G. Frau,et al.  [Anatomy and physiology of the nose]. , 1994, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[11]  V. Zecchi,et al.  Chitosan microcapsules as controlled release systems for insulin. , 1997, Journal of microencapsulation.

[12]  H. Junginger,et al.  Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. , 2003, Vaccine.

[13]  Joseph L. Kanig,et al.  The theory and practice of industrial pharmacy , 1970 .

[14]  S. Patil,et al.  Preparation and in vitro evaluation of mucoadhesive chitosan microspheres of amlodipine besylate for nasal administration , 2006 .

[15]  S. Davis,et al.  In vitro evaluation of the mucoadhesive properties of chitosan microspheres , 1998 .

[16]  Michael K. Taylor,et al.  Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development , 2000, AAPS PharmSciTech.

[17]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[18]  S. F. Chang,et al.  Chitosan microspheres: modification of polymeric chem-physical properties of spray-dried microspheres to control the release of antibiotic drug , 1999 .

[19]  M. Tafaghodi,et al.  Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. , 2004, International journal of pharmaceutics.

[20]  O. Damour,et al.  Optimization of thickness, pore size and mechanical properties of a biomaterial designed for deep burn coverage. , 1994, Clinical materials.

[21]  A. Allen,et al.  A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain [proceedings]. , 1978, Biochemical Society transactions.

[22]  S. Davis,et al.  Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. , 2001, International journal of pharmaceutics.

[23]  N. Peppas,et al.  Structure and Interactions in Covalently and Ionically Crosslinked Chitosan Hydrogels for Biomedical Applications , 2003 .

[24]  G. Roberts,et al.  Chitosan gels, 3. The formation of gels by reaction of chitosan with glutaraldehyde , 1989 .

[25]  A. Bernkop‐Schnürch,et al.  Thiolated polymers--thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. , 2003, International journal of pharmaceutics.

[26]  Lena Pereswetoff-Morath,et al.  Microspheres as nasal drug delivery systems. , 1998, Advanced drug delivery reviews.

[27]  P. Buri,et al.  Nasal mucosa as an absorption barrier , 1994 .

[28]  P. Buri,et al.  A novel in situ method to test polymers and coated microparticles for bioadhesion , 1989 .

[29]  M I Ugwoke,et al.  The biopharmaceutical aspects of nasal mucoadhesive drug delivery , 2001, The Journal of pharmacy and pharmacology.

[30]  N Verbeke,et al.  Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. , 2000, International journal of pharmaceutics.

[31]  A. Perkins,et al.  Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.

[32]  M. D. Blanco,et al.  Chitosan microspheres in PLG films as devices for cytarabine release. , 2000, International journal of pharmaceutics.

[33]  I Horikoshi,et al.  Optimization of the formulation design of chitosan microspheres containing cisplatin. , 1996, Journal of pharmaceutical sciences.

[34]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[35]  L. Illum.  Nasal drug delivery: new developments and strategies. , 2002, Drug discovery today.

[36]  María J. Alonso,et al.  Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration , 1999 .

[37]  A. Jayakrishnan,et al.  Cross‐linked Chitosan Microspheres: Preparation and Evaluation as a Matrix for the Controlled Release of Pharmaceuticals , 1992, The Journal of pharmacy and pharmacology.

[38]  S Somavarapu,et al.  Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. , 2005, Advanced drug delivery reviews.

[39]  L. Illum.  BIOADHESIVE FORMULATIONS FOR NASAL PEPTIDE DELIVERY , 1999 .